Publications

Export 34 results:
Sort by: Author [ Title (Asc)] Type Year
Filters: First Letter Of Title is O  [Clear All Filters]
A B C D E F G H I J K L M N [O] P Q R S T U V W X Y Z   [Show ALL]
O
Mattsson C, Lai M, Noble J, McKinney E, Yau JL, Seckl JR, et al. Obese Zucker rats have reduced mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 1 expression in hippocampus-implications for dysregulation of the hypothalamic-pituitary-adrenal axis in obesity. Endocrinology. 2003;144:2997-3003. Abstract
Morton NM. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol. 2010;316(2):154-64. Abstract
Sharpe RM, Drake AJ. Obesogens and obesity: An alternative view. Obesity. 2013.
Morrison EE, Turtle EJ, Webb DJ. Observing the NICEties of hypertension management. J R Coll Physicians Edinb. 2012;42(3):251-7. Abstract
Ho CK, Nanda J, Chapman KE, Habib FK. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. The Journal of endocrinology. 2008;197:483-91. Abstract
Gray GA, Sharif I, Webb DJ, Seckl JR. Oestrogen and the cardiovascular system: the good, the bad and the puzzling. Trends in pharmacological sciences. 2001;22:152-6. Abstract
Jeanes HL, Tabor C, Black D, Ederveen A, Gray GA. Oestrogen-mediated cardioprotection following ischaemia and reperfusion is mimicked by an oestrogen receptor (ER)alpha agonist and unaffected by an ER beta antagonist. The Journal of endocrinology. 2008;197:493-501. Abstract
Michailidou Z, Jensen MD, Dumesic DA, Chapman KE, Seckl JR, Walker BR, et al. Omental 11beta-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity. Obesity (Silver Spring). 2007;15(5):1155-63. Abstract
Mpamhanga CP, Spinks D, Tulloch LB, Shanks EJ, Robinson DA, Collie IT, et al. One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening. J Med Chem. 2009;52(14):4454-65. Abstract
Morrow DA, Antman EM, Fox KA, White HD, Giugliano R, Murphy SA, et al. One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial. Eur Heart J. 2010;31(17):2097-102. Abstract
Zhao Y, Bader M, Kreutz R, Fernandez-Alfonso M, Zimmermann F, Ganten U, et al. Ontogenetic regulation of mouse Ren-2d renin gene in transgenic hypertensive rats, TGR(mREN2)27. The American journal of physiology. 1993;265:E699-707. Abstract
Péault B, Coltey M, Le Douarin NM. Ontogenic emergence of a quail leukocyte/endothelium cell surface antigen. Cell Differ. 1988;23(3):165-74. Abstract
Blazsek I, Chagraoui J, Péault B. Ontogenic emergence of the hematon, a morphogenetic stromal unit that supports multipotential hematopoietic progenitors in mouse bone marrow. Blood. 2000;96(12):3763-71. Abstract
Brown RW, Diaz R, Robson AC, Kotelevtsev YV, Mullins JJ, Kaufman MH, et al. The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. Endocrinology. 1996;137:794-7. Abstract
Hundertmark S, Bühler H, Fromm M, Kruner-Gareis B, Kruner M, Ragosch V, et al. Ontogeny of 11beta-hydroxysteroid dehydrogenase: activity in the placenta, kidney, colon of fetal rats and rabbits. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme. 2001;33:78-83. Abstract
Speirs HJ, Seckl JR, Brown RW. Ontogeny of glucocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type-1 gene expression identifies potential critical periods of glucocorticoid susceptibility during development. The Journal of endocrinology. 2004;181:105-16. Abstract
Bean R, Seckl JR, Lathe R, Martin C. Ontogeny of the neurosteroid enzyme Cyp7b in the mouse. Molecular and cellular endocrinology. 2001;174:137-44. Abstract
Langrish JP, Fox KA. Optimal antithrombotic treatment during primary percutaneous coronary intervention? Heart. 2011;97(18):1459-60.
Langrish JP, Fox KA. Optimal antithrombotic treatment during primary percutaneous coronary intervention? Heart. 2011;97(18):1459-60.
Turban S, Liu X, Ramage L, Webster SP, Walker BR, Dunbar DR, et al. Optimal Elevation of β-Cell 11β-Hydroxysteroid Dehydrogenase Type 1 Is a Compensatory Mechanism that Prevents High Fat Diet-Induced β-Cell Failure. Diabetes. 2012. Abstract
MacColl GS, Novo FJ, Marshall NJ, Waters M, Goldspink G, Bouloux PM. Optimisation of growth hormone production by muscle cells using plasmid DNA. The Journal of endocrinology. 2000;165:329-36. Abstract
Levy L, Broad S, Zhu AJ, Carroll JM, Khazaal I, Péault B, et al. Optimised retroviral infection of human epidermal keratinocytes: long-term expression of transduced integrin gene following grafting on to SCID mice. Gene Ther. 1998;5(7):913-22. Abstract
Baillie JK, Thompson AA, Irving JB, Bates MG, Sutherland AI, Macnee W, et al. Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial. QJM. 2009;102(5):341-8. Abstract
Dweck MR, Newby DE. Osteoporosis is a major confounder in observational studies investigating bisphosphonate therapy in aortic stenosis. J Am Coll Cardiol. 2012;60(11):1027; author reply 1027.
Wedderburn CJ, van Beijnum J, Bhattacharya JJ, Counsell CE, Papanastassiou V, Ritchie V, et al. Outcome after interventional or conservative management of unruptured brain arteriovenous malformations: a prospective, population-based cohort study. Lancet Neurol. 2008;7(3):223-30. Abstract